Literature DB >> 8788493

Novel discriminatory ligands for 5-HT2B receptors.

G S Baxter1.   

Abstract

The 5-HT2B receptor is the most recent addition to the 5-HT2 receptor family and shares strong operational similarities with the structurally related 5-HT2A and 5-HT2C receptor subtypes. The strength of the pharmacological association, particularly between 5-HT2B and 5-HT2C receptors, suggests a need to consider carefully the use of ligands which may now be regarded as somewhat non-selective for the receptors in this class. The possibility that biological activity previously supposed to involve 5-HT2C receptors may actually involve 5-HT2B receptors highlights a need to develop ligands with improved selectivity profiles. In this regard, medicinal chemistry continues to provide novel ligands which, if truly selective, should facilitate our understanding of the physiology, pathophysiology and therapeutic potential of 5-HT2B receptor modulation. This article reviews some of the newest ligands which may be used in the discrimination and characterisation of 5-HT2B receptor function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788493     DOI: 10.1016/0166-4328(96)00087-3

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

1.  Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors.

Authors:  E Glusa; H H Pertz
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs.

Authors:  Luis F Valdivia; David Centurión; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-06-29       Impact factor: 3.000

3.  RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Authors:  D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

4.  Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.

Authors:  S Jähnichen; E Glusa; H H Pertz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-12-04       Impact factor: 3.000

5.  Serotonergic 5-HT(2B) receptor controls tissue-nonspecific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase C.

Authors:  Anne Baudry; Juliette Bitard; Sophie Mouillet-Richard; Morgane Locker; Anne Poliard; Jean-Marie Launay; Odile Kellermann
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

6.  Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.

Authors:  R H Porter; K R Benwell; H Lamb; C S Malcolm; N H Allen; D F Revell; D R Adams; M J Sheardown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors.

Authors:  Katherine C Murray; Marilee J Stephens; Michelle Rank; Jessica D'Amico; Monica A Gorassini; David J Bennett
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

Review 8.  Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.

Authors:  Terry-Elinor Reid; Krishna Kumar; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

9.  Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans.

Authors:  Hedvig Bennet; Inês G Mollet; Alexander Balhuizen; Anya Medina; Cecilia Nagorny; Annika Bagge; Joao Fadista; Emilia Ottosson-Laakso; Petter Vikman; Marloes Dekker-Nitert; Lena Eliasson; Nils Wierup; Isabella Artner; Malin Fex
Journal:  Diabetologia       Date:  2016-01-06       Impact factor: 10.122

10.  The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.

Authors:  D T Beattie; J A M Smith; D Marquess; R G Vickery; S R Armstrong; T Pulido-Rios; J L McCullough; C Sandlund; C Richardson; N Mai; P P A Humphrey
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.